C11719: Drug to Prevent Alcohol ToxicityNovelty:
The technology involves the use of dietary chemicals to reduce the unpleasant symptoms associated with alcohol consumption and reduce the risk of serious diseases.
Value Proposition:
Alcohol toxicity from the consumption of a large amount of alcohol in a short period of time can lead to many adverse symptoms and health problems. This technology is one-of-a-kind therapeutic that detoxifies alcohol and metabolizes acetaldehyde faster causing less damage to cells. This is particularly useful in certain populations in which ALDH2 polymorphisms, causing higher sensitivity to alcohol, are common. Key advantages of this technology are:
• Therapeutic is derived from natural phytochemicals
• Prevents serious consequences like tachycardia, damage to liver, heart, nervous system, etc
• Reduces risk for cancer and other serious diseases
• Ready for clinical trials: FDA-approved INDs and IRB permission for the oral administration of such extracts for other indications
Technical Details:
Johns Hopkins researchers have discovered a natural extract that upregulates aldehyde dehydrogenase (ALDH). After consumption, alcohol is converted to acetaldehyde, which is highly toxic and needs to be converted to non-toxic compounds by ALDH2. This rate-limiting step is the target of the technology. The drug upregulates ALDH2 and causes faster detoxification of alcohol and thus reducing the undesirable effects associated with alcohol consumption.
Looking for Partners:
To develop and commercialize the technology as a preventative drug for avoiding symptoms and diseases caused by alcohol toxicity.
Stage of Development:
Discovery
Data Availability:
Under CDA/NDA
Publications/Associated Cases:
Chemical assays
